Recommended dosage and medication instructions for zolbetuximab

Zolbetuximab (Zolbetuximab) is a humanized IgG1 monoclonal antibody for targeted therapy. It mainly targets mucin 1 (Claudin) which is highly expressed in gastric cancer and gastroesophageal junction adenocarcinoma. 18.2, CLDN18.2) target. The drug was developed by Astellas. It belongs to a new generation of tumor immunotherapy drugs and has shown good efficacy and controllable safety in multiple international clinical trials. It is especially suitable for patients with CLDN18.2 positive expression. Zotuximab is often combined with platinum- and fluorouracil-based chemotherapy in treatment regimens. This article will give a systematic explanation of its recommended dosage, administration method and medication specifications.

1. Recommended dosage of zotuximab at one time

In clinical studies, the recommended standard dose of zotuximab is 800 mg/m intravenously as the first loading dose, followed by maintenance doses of 600 mg/m every three weeks. The dosage is calculated based on the patient's body surface area, which is generally between 1.6 m² and 2.0 m². Therefore, the actual single dose is usually in the range of 1000 mg to 1600 mg. The specific dose should be accurately calculated by the doctor based on the patient's body surface area to ensure therapeutic effect and safety.

Zotuximab is an intravenous infusion preparation, and the first infusion time is usually no less than 120 minutes to reduce the incidence of infusion-related reactions. If the patient tolerates the first dose well, subsequent doses can be completed in approximately 90 minutes. The drug solution needs to be diluted before injection. It is recommended to use 0.9% sodium chloride injection to dilute it to an appropriate concentration and infuse it under close monitoring by medical staff.

2. Combined medication and medication cycle

In standard treatment, zotuximab is often used in combination with first-line chemotherapy regimens such as FOLFOX (oxaliplatin + leucovorin + fluorouracil). By acting synergistically with chemotherapy drugs, the drug not only increases the apoptosis rate of tumor cells, but also helps enhance the immune system's ability to recognize tumors. In terms of medication cycle, a course of treatment is usually 21 days, and one injection of zotuximab is completed within each course of treatment. The entire treatment may last 6 to 8cycle, or longer, depending on the patient's response to treatment and adverse events to determine whether to extend or discontinue treatment.

3. Medication specifications and precautions

The use of zotuximab must strictly follow professional regulations. Before use, the expression level of Claudin 18.2 in the patient's tumor tissue needs to be confirmed through immunohistochemistry. Only patients with positive expression of CLDN18.2 (generally defined as the proportion of positive cells ≥ 75%) can have a clear therapeutic effect. In addition, to reduce allergic reactions, pretreatment with antihistamines, antipyretic analgesics, or corticosteroids is recommended before the first dose.

During the treatment process, infusion-related reactions need to be closely observed, especially when the first dose is administered. If discomfort such as fever, chills, rash, difficulty breathing, etc. occurs, the infusion should be suspended immediately and symptomatic treatment should be given. Patients with a history of severe allergies should be treated with extreme caution and alternative treatment options should be considered if necessary.

During the entire treatment cycle, the patient's blood routine, liver and kidney function, electrolyte levels and other indicators should be regularly monitored in order to promptly detect and manage adverse reactions caused by the drug, such as neutropenia, nausea and vomiting, diarrhea, electrolyte imbalance, etc. In addition, because zotuximab is a protein drug with certain immunogenicity, long-term use may produce drug resistance or neutralizing antibodies, and the treatment effect and disease progression need to be monitored.

4. Individualized treatment suggestions and future prospects

Although the recommended dosage and regimen of zotuximab have been clinically verified, different patients have differences in drug response, tolerance, and combination treatment methods. Therefore, clinicians should conduct comprehensive assessment and dose adjustment based on individual factors such as patient age, body surface area, comorbid underlying diseases, and previous medication history. For example, for elderly and frail patients or patients with poor tolerance to chemotherapy, appropriate extension of the dosing interval or adjustment of the intensity of combined medication may be considered. If serious adverse reactions occur, treatment should be temporarily suspended and then evaluated whether to resume medication after symptoms are relieved.

Currently, zotuximab is undergoing multiple indication expansion studies, such as advanced pancreatic cancer, esophageal cancer, etc. It also shows certain therapeutic potential in solid tumors expressing Claudin 18.2. In the future, with the popularization of CLDN18.2 target detection technology and the improvement of drug combination strategies, zotuximab is expected to become an important part of precision medicine and bring new treatment hope to more patients with advanced solid tumors.

To sum up, zotuximab is an anti-tumor monoclonal antibody drug with strong targeting and clear efficacy. Its recommended dosage at one time must be accurately calculated based on the patient's body surface area and administered according to standard procedures in a standardized medical environment. In clinical application, attention should be paid to combined medication methods, treatment cycle arrangements and individual differences management to achieve the treatment goals of maximum efficacy and minimum toxic side effects.

Reference:https://www.astellas.com/en/news/29401